Business Context and Reporting Period
Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: LabCorp operates as a leading provider of clinical laboratory testing services. The company maintains significant relationships with managed care organizations, including a major ten-year exclusive agreement with UnitedHealthcare effective January 1, 2007.
Key Financial Metrics
All figures in millions, except per share data.
| Metric | Three Months Ended June 30, 2007 |
Six Months Ended June 30, 2007 |
|---|---|---|
| Net Sales | $1,043.1 | $2,041.8 |
| Cost of Sales | $601.1 | $1,178.1 |
| Gross Profit | $442.0 | $863.7 |
| Operating Income | $212.5 | $415.9 |
| Net Earnings | $128.7 | $251.2 |
| Diluted EPS | $1.05 | $2.03 |
| Cash from Operations (6mo) | $338.9 | |
| Capital Expenditures (6mo) | $73.0 | |
| Total Debt (Current + Long-term) | $1,161.9 | |
| Cash and Equivalents | $8.5 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15.4% ($139.4M) for the quarter and 14.6% ($259.6M) for the six-month period compared to 2006. Growth was driven by a 14.2% increase in accession volume (primarily Managed Care) and a 1.2% price increase.
- Cost Structure: Cost of sales rose 17.7% for the quarter, outpacing revenue growth. Gross margin decreased from 43.5% to 42.4% (quarterly) due to the rollout of patient service centers and increased material costs.
- Restructuring Charges: The company recorded $7.0 million in restructuring charges for the quarter, primarily for facility closures and employee severance (approx. 170 employees). No such charges were recorded in the comparable 2006 period.
- Share Repurchases: The company repurchased 5.8 million shares for $409.5 million during the first six months of 2007, compared to $222.9 million in the prior year period.
- Liquidity: Cash and cash equivalents decreased from $51.5 million at year-end 2006 to $8.5 million at June 30, 2007, largely due to share repurchases and capital expenditures.
Guidance, Outlook, and Risks
- Managed Care Contracts:
- UnitedHealthcare: LabCorp is the exclusive national laboratory. The company committed to reimbursing up to $200 million in transition costs over three years. Approximately $16.7 million was billed in the first half of 2007. Management estimates total costs will be ~25% less than the contractual limit.
- Aetna: LabCorp lost its contracted provider status effective July 1, 2007, placing direct revenue at risk.
- CIGNA: Renewed multi-year contract; restrictions on marketing as an in-network provider will expire January 1, 2008.
- Capital Expenditures: Expected to be between $130 million and $140 million for fiscal 2007, funded by operating cash flow and credit facilities.
- Debt and Convertibles: The company has $559.1 million in zero-coupon convertible subordinated notes (LYONs and Zero Coupon Notes). Holders may convert these notes through October 1, 2007. Contingent cash interest of approx. $1.22 per note is payable in September 2007.
- Risk Factors: Key risks include changes in reimbursement regulations, adverse results from government investigations, loss of licenses, and the impact of the Aetna contract termination. The company faces ongoing litigation regarding patent infringement and False Claims Act allegations, though management does not expect a material adverse effect.
Investor Verification Checklist
- UnitedHealthcare Transition Costs: Verify the actual total cost of the $200 million transition commitment against the management estimate of a 25% reduction.
- Aetna Revenue Impact: Monitor future quarters for the specific revenue decline resulting from the loss of the Aetna contract effective July 1, 2007.
- Debt Conversion: Assess the potential dilution or cash outflow if holders convert the $559.1 million in zero-coupon notes by the October 1, 2007 deadline.
- Liquidity Position: Review the low cash balance ($8.5 million) relative to the $111.1 million in letters of credit and upcoming capital expenditure needs.
- Margin Compression: Track whether the gross margin decline (due to service center rollouts) stabilizes or continues to widen in subsequent quarters.